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Nonalcoholic fatty liver disease (NAFLD) is now recognized as a major cause of chronic liver diseases, including liver cirrhosis and hepatocellular carcinoma (HCC) in Western countries. 1, 2 Like alcoholic liver disease, NAFLD covers a wide spectrum of disorders from simple steatosis to nonalcoholic steatohepatitis (NASH) and
cirrhosis. Approximately 30% of the US population and 20% of the Korean population have NAFLD. 1, 3 Just as all heavy drinkers do not progress to cirrhosis and HCC, nor do all patients with nonalcoholic steatosis progress. In addition to its high prevalence, one of the challenges facing hepatologists is the diagnosis and risk stratification of NAFLD. There is no proven serologic marker to confirm the disease, which is diagnosed by excluding a history of alcohol consumption and other causes of liver disease using various serologic tests; sometimes a liver biopsy is needed. Moreover, after the diagnosis, it is not clear who will progress to cirrhosis or HCC.
Central obesity is a well-known risk factor and hyper- 
